Drugs Made In America Acquisition (NASDAQ:DMAA) Posts Quarterly Earnings Results

Drugs Made In America Acquisition (NASDAQ:DMAA) posted its quarterly earnings results on Thursday. The company reported $0.06 earnings per share (EPS) for the quarter, FiscalAI reports.

Drugs Made In America Acquisition Trading Down 0.0%

Shares of NASDAQ DMAA traded down $0.00 during mid-day trading on Friday, hitting $10.59. 102 shares of the company traded hands, compared to its average volume of 100,374. Drugs Made In America Acquisition has a 1 year low of $10.10 and a 1 year high of $10.60. The business has a 50 day moving average of $10.52 and a two-hundred day moving average of $10.43.

Institutional Trading of Drugs Made In America Acquisition

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Wolverine Asset Management LLC boosted its holdings in shares of Drugs Made In America Acquisition by 4.7% in the fourth quarter. Wolverine Asset Management LLC now owns 1,307,468 shares of the company’s stock worth $13,564,000 after buying an additional 58,340 shares during the period. Mercuria Capital Strategies LLC acquired a new position in shares of Drugs Made In America Acquisition in the fourth quarter worth $7,511,000. Boothbay Fund Management LLC acquired a new position in Drugs Made In America Acquisition in the 2nd quarter worth about $5,814,000. Radcliffe Capital Management L.P. raised its position in Drugs Made In America Acquisition by 3.5% during the fourth quarter. Radcliffe Capital Management L.P. now owns 546,808 shares of the company’s stock valued at $5,673,000 after acquiring an additional 18,708 shares in the last quarter. Finally, Rivernorth Capital Management LLC lifted its stake in shares of Drugs Made In America Acquisition by 31.4% in the 4th quarter. Rivernorth Capital Management LLC now owns 417,998 shares of the company’s stock valued at $4,335,000 after purchasing an additional 100,000 shares during the last quarter.

Drugs Made In America Acquisition Company Profile

Drugs Made In America Acquisition Corp (NASDAQ: DMAA) is a special purpose acquisition company incorporated in Delaware with the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. The company’s stated focus is on identifying and acquiring one or more operating businesses in the U.S. pharmaceutical sector, particularly those involved in the domestic manufacturing of approved drugs, active pharmaceutical ingredients or related contract development and manufacturing services.

Operating as a blank‐check vehicle, Drugs Made In America Acquisition holds its funds in a trust account pending the completion of an initial business combination.